HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),…
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support…
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway…
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,…
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed…
Enrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan’s ability to improve surgical…
PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative…
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients…
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").…
image1 VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the…